Rexgenero: Tackling Critical Limb Ischemia With Cell Therapy Approach
Executive Summary
Emerging Company Profile: Rexgenero is developing a cell therapy to treat critical limb ischemia and is in the process of raising €25m to fund the Phase III program on top of €60m the company has raised to date. CEO Joe Dupere spoke with Scrip's Mike Ward at the Biotech Showcase last month.